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Prenatal exposure to inorganic arsenic (iAs) has been associated with adverse 
developmental and reproductive outcomes, and may be tied to altered glucocorticoid receptor 
(GR) in the placenta. In this study, we investigated whether iAs exposure modulates GR 
signaling in placental cells. Trophoblast JEG-3 cells were exposed to environmentally-
relevant doses of iAs and mRNA expression and DNA methylation were quantified. Results 
demonstrated that iAs exposure alters the expression of 12 GR-genes that play a role in fetal 
and placental development. Furthermore, supporting a role for the epigenome in control of 
this expression, the mRNA alterations were associated with changes in DNA methylation 
patterning in placental cells. The identified target genes have been implicated in associations 
with prenatal arsenic exposure, placental physiology, and fetal development. This study 
provides evidence of iAs as an endocrine disruptor and insight into the mechanisms by which 
prenatal iAs exposure induces adverse birth outcomes.  
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CHAPTER 1: INTRODUCTION 
 Inorganic arsenic (iAs) is an ubiquitous contaminant representing a worldwide health 
concern as more than 100 million individuals are exposed to potentially harmful levels of 
arsenic in drinking water that exceeds the World Health Organization’s (WHO) limit of 10 
μg/L (Naujokas et al., 2013). In the United States alone, arsenic has been found to be present 
in drinking water at levels that exceed 800 μg/L (Sanders et al., 2012). These exposures are a 
significant public health concern as they have been associated with skin lesions, diabetes 
mellitus, cancer, and high blood pressure in adult populations (Naujokas et al., 2013; Yunus, 
Sohel, Hore, & Rahman, 2011).  
Early life exposures to inorganic arsenic are associated with adverse reproductive and 
developmental outcomes such as preterm birth, low birth weight, and susceptibility to 
infection, among others (Naujokas et al., 2013; Bailey et al., 2016). Additionally, prenatal 
exposure to inorganic arsenic exposure may cause spontaneous abortion, stillbirth, and infant 
mortality (Rahman et al., 2007; Rahman et al., 2010). Previously, the molecular mechanisms 
that underlie these observed health outcomes associated with arsenic exposure have been 
thought to be related to arsenic’s ability to induce epigenetic modifications, which have been 
shown to mediate disease development and susceptibility (Laine & Fry, 2016; Smeester & 
Fry, 2018; Bailey & Fry, 2014; Kile et al., 2014; Green et al., 2016; Appleton, Jackson, 
Karagas, & Marsit, 2017).  
Of relevance to arsenic-induced developmental outcomes, inorganic arsenic has been 
shown to cross the placenta, which subsequently leads to fetal exposure and modulation of 
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the fetal epigenome (Concha, Vogler, Lezcano, Nermell, & Vahter, 1998). Furthermore, 
placental arsenic concentrations have been shown to correlate with fetal and maternal blood 
concentrations, which provides a basis for the utilization of placental tissue as a primary 
organ of interest to quantify fetal exposures during development (Punshon et al., 2015). 
Additionally, previous studies have demonstrated arsenic’s ability to accumulate in placental 
tissue once arsenic crosses the placental barrier (Punshon et al., 2015). The placenta acts as 
an endocrine organ during fetal development and mediates fetal exposures to exogenous 
compounds (Evain-Brion & Malassine, 2003; Burton, Fowden, & Thornburg, 2016). Other 
functions of the placenta include regulating fetal nutrition, controlling the production of fetal 
and maternal cortisol, producing additional hormones key for fetal development such as 
growth factors and cytokines, and ultimately controls the fetal environment (Novakovic & 
Saffery, 2012; Godfrey, 2002; Kertes et al., 2016; De Bonis et al., 2012). Additionally, the 
placenta also acts as driver of early and later life outcomes and functions as a biosensor for 
environmental exposures and impacts on later life health (Maccani & Marsit, 2009). Taken 
together, there is substantial evidence for the use of placental tissues to quantify epigenetic 
marks that may result from environmental iAs exposures in utero that may mediate early and 
later in life health outcomes.  
Previously arsenic has been shown to act as a potential endocrine disruptor (Sun, Sun, 
Xiang, Luo, & Hong, 2016). For example, in non-placental hepatic cells, arsenic has been 
shown to display a non-monotonic dose relationship where lower concentrations (0.1-1 μM) 
induce activity but higher concentrations (2-3 μM) repressing activity (Bodwell, Kingsley, & 
Hamilton, 2004). The specific molecular mechanisms by which arsenic alters activity of the  
glucocorticoid receptor (GR) pathway and acts as an endocrine disruptor remain relatively 
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understudied. However, it is well established that epigenetic modifications, such as DNA 
methylation, may underlie the arsenic-associated modulation of biological pathways 
associated with adverse health outcomes and placental gene expression (Laine & Fry, 2016; 
Green et al., 2016; Sun et al., 2016; Rojas et al., 2015).  
The observed activation of the GR-pathway could potentially be linked to DNA 
methylation patterning through the transcription factor occupancy (TFO) theory (Martin & 
Fry, 2016). This theory posits that DNA methyltransferase cannot gain access to DNA when 
transcription factors have bound to and occupied response elements of selected genes, 
thereby influencing CpG methylation patterning and subsequent gene expression (Martin & 
Fry, 2016; Zhu, Wang, & Qian, 2016). This is significant as disruptions in placental 
pathophysiology in utero have been linked to functional outcomes such as cardiovascular 
disease and hypertension later in life (Barker, Bull, Osmond, & Simmonds, 1990). 
Additionally, epigenetic marks in the placenta have been associated with cognitive 
functioning in newborns (Appleton et al., 2017; Paquette et al., 2015; Paquette et al., 2014; 
Conradt, Lester, Appleton, Armstrong, & Marsit, 2013; Monk et al., 2016).  Specifically, 
DNA methylation of the glucocorticoid receptor, NR3C1, has been shown to impact fetal 
behavior and neurocognition (Paquette et al., 2015; Conradt et al., 2013; Bromer, Marsit, 
Armstrong, Padbury, & Lester, 2013). Taken together, this data demonstrates the ability of in 
utero arsenic exposure to disrupt endocrine associated pathways, such as the GR-pathway, 
which may have functional outcomes later in life.  
With respect to biological pathways associated with fetal exposures and adverse 
health outcomes, the GR-pathway has been shown to mediate the effects of stress during 
pregnancy on the developing fetus (Cottrell & Seckl, 2009).  The GR serves as the master 
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regulator of glucocorticoid action during fetal development and throughout the life course of 
an individual (Zannas & Chrousos, 2017; Emin Turkay Korgun, 2012). When 
glucocorticoids, such as cortisol and corticosterone, bind to the GR, the GR dimerizes and 
enters the nucleus and subsequently binds to DNA response elements. Downstream genes of 
glucocorticoid response elements (GRE) have been shown to affect placental and fetal 
growth, development, and function (Emin Turkay Korgun, 2012; Moisiadis & Matthews, 
2014). While excess exposures to glucocorticoids have been associated with adverse fetal 
outcomes, glucocorticoids are necessary for proper fetal and placental development 
(Moisiadis & Matthews, 2014; Ozmen, Unek, & Korgun, 2017; Bivol, Owen, & Rose'Meyer, 
2016; Fowden & Forhead, 2015). Specific developments driven by glucocorticoid 
programming include the heart, the brain, the lungs, the kidneys, and maturation of the fetal 
HPA axis (Moisiadis & Matthews, 2014). Due to the integral nature of glucocorticoid 
exposure during fetal development, aberrations in the GR-signaling pathway have been 
associated with fetal abnormalities and potentially lifelong adverse health effects (Ozmen et 
al., 2017; Bivol et al., 2016). Furthermore, the gene that encodes for the GR (NR3C1) is 
highly expressed in the placenta and modulation of the GR-pathway in the placenta and other 
tissues have been associated with aforementioned neurobehavioral outcomes, cardiovascular 
disease, cancer, and inflammatory disease (Paquette et al., 2015; Monk et al., 2016; Emin 
Turkay Korgun, 2012; Argentieri, Nagarajan, Seddighzadeh, Baccarelli, & Shields, 2017).  
Literature that details arsenic’s role in modifying the placental glucocorticoid pathway 
are limited. Given the evidence that arsenic modulates fetal disease development and may act 
as an endocrine disruptor, we determined the effects of arsenic exposure on placental GR-
gene expression. We hypothesized that increased iAs exposure would result in a significant 
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alteration of mRNA gene expression levels that would reflect previous studies where lose 
doses of arsenic exposure induce GR-gene expression and higher doses of arsenic repress 
GR-gene expression. Additionally, we hypothesized these changes in expression are 
significantly associated with DNA methylation patterning in placental cells, leading to 
functional outcomes associated with disease. In this novel study, we are among the first to 
examine GR-pathway response to arsenic exposure in the placenta. Placental JEG-3 cells 
were treated with levels of inorganic arsenic at environmentally-relevant, non-cytotoxic 
doses at concentrations of 0.5, 1, and 3 M iAs. Isolated DNA and RNA were used to 
quantify DNA methylation and GR-pathway gene expression. 
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CHAPTER 2: METHODS 
Cell Culture and iAs Treatments 
 The JEG-3 choriocarcinoma cell line was purchased from the American Type Culture 
Collection (Manassas, VA). JEG-3 cells were grown in Dulbecco’s modified Eagle’s 
Minimum Essential Medium, supplemented with 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin, and 1mM sodium pyruvate at 37 C in 50% CO2. Cells were plated 
at 5 x 106 cells per 25cm3 flask and incubated under standard conditions until achieving 80-
90% confluence. In order to investigate the effects of iAs in vitro, JEG-3 cells were cultured 
in a 6-well culture plate for 24 at 0.5 x 106 cells per well. iAs was dissolved in deionized 
water and vortexed to create final concentrations of 0.5 M, 1 M, and 3 M iAs. Cells were 
exposed to these concentrations of iAs for 24 h, at which point cells were harvested for DNA 
and RNA isolation. Vehicle controls were treated with Dulbecco’s modified Eagle's 
Minimum Essential Medium, supplemented with 10% FBS, 1% penicillin/streptomycin, and 
1mM sodium pyruvate for 24 h.  
mRNA Expression Assessment by Quantitative Real-Time Polymerase Chain Reaction (RT-
PCR) 
Treated and untreated JEG-3 cells were harvested using ice cold PBS and Buffer 
RLT. Harvested cells were then placed in a QIAcube (Qiagen, Valencia CA) for RNA and 
DNA extraction according to the manufacturer’s protocol. Subsequent extracted RNA were 
quantified through the use of a Nanodrop 1000 spectrophotometer (Thermo Scientific, 
Waltham, MA). RNA integrity was analyzed with the use of the QIAxcel Screengel (Qiagen, 
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Valencia CA) according the manufacturer’s protocol. Extracted RNA was converted to 
cDNA and subsequent mRNA expression was analyzed with the RT² Profiler™ PCR Array 
for Human Glucocorticoid Signaling, which quantifies 84 genes that are downstream targets 
of the GR-pathway, according to the manufacturer’s protocol (Qiagen, Valencia CA)). 
Results of RT-PCR cycle times were normalized against the housekeeping gene Beta-
actin (ACTB), and fold changes in expression were calculated based on the CT method 
(Livak & Schmittgen, 2001). 
DNA Methylation Analysis 
 Extracted DNA were quantified through the use of a Nanodrop 1000 
spectrophotometer (Thermo Scientific). To analyze placental CpG methylation, extracted 
DNA sequences were sent to Wayne State (Detroit, MI) and bisulfate-converted using the EZ 
DNA methylation kit (Zymo Research, Irvine, CA) and then subsequently hybridized on the 
Illumina HumanMethylation850 Bead Chip array (Illumina, Inc., San Diego, CA), which 
assesses the DNA methylation levels of 853,307 individual probes at single nucleotide 
resolution. Methylation levels were calculated and expressed as  values (= intensity of the 
methylated allele (M)/ [intensity of the unmethylated allele (U) + intensity of the methylated 
allele (M) + 100. Data were normalized for both arrays using the minfi package in R (Aryee 
et al., 2014). Specifically, image files were used to produce background-corrected and 
quantile normalized β-values. 
Statistical Analysis  
Each experiment was performed in biological triplicate. Statistically significant 
findings are reported as the mean value ± the standard error of the mean (SEM). DNA 
methylation and mRNA expression changes between exposed and unexposed cells were 
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analyzed using a one-way analysis of variance (ANOVA) in Partek® Genomics Suite 
Softwate (St. Lewis, MO). In order to investigate direct comparisons, a post-hoc Tukey test 
was utilized. Statistical significance was set at a Bonferroni corrected p<0.05 (McDonald, 
2014). For the purposes of identifying biological functions and regulators associated with an 
identified gene set, Ingenuity Pathway Analysis (IPA) was used. Significant pathways 





CHAPTER 3: RESULTS 
 In order to gain insight as to whether iAs exposure modulates expression of genes 
involved in the GR-signaling pathway, isolated mRNA was extracted from exposed JEG-3 
cells and analyzed with a Qiagen GR-signaling array, which measures mRNA expression of 
84 GR target genes (Qiagen, Valencia CA). Results demonstrated iAs exposure to induce a 
significant alteration (p<0.05) in mRNA expression amongst 12 GR-signaling genes 
represented in FIGURE 1.  
 
Figure 1. mRNA expression heatmap displaying the 12 genes that demonstrated 
significant (p<0.05) altered mRNA expressing with iAs treatment.  
A total of 12 genes displayed a significant alteration (p<0.05) in mRNA expression with 
inorganic arsenic treatment relative to controls. Red coloring denotes an increase in 
expression while blue coloring indicates a decrease in expression.  
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Specifically, three genes displayed an increase in expression as iAs exposure increased (0.5-3 
M), which included Metallothionein 2A (MT2A), AF4/FMR2 family, member 1 (AFF1), 
SplA/ryanodine receptor domain and SOCS box containing 1 (SPSB1). Conversely, 
Aquaporin 1 (AQP1) displayed a decrease in expression across all treatment groups relative 
to controls. Serum/GC-regulated kinase 1 (SGK1) demonstrated a dose-response relationship 
where decreases in mRNA expression were observed at 0.5 M iAs and increases in mRNA 
expression at increasing treatments of 1-3 M iAs. An additional seven genes displayed a 
unique trend where low doses (0.5-1 M iAs) resulted in an increase in mRNA expression, 
but the (1-3 M iAs) doses caused a reduction in mRNA expression. These genes were 
Period Homolog 2 (PER2), AT Rich Interactive Domain 5B (ARID5B), Hexose-6-phosphate 
dehydrogenase (H6PD), Cytochrome b-561 (CYB561), Zinc Fingers and Homeoboxes 
(ZHX3), Solute carrier family 22 (organic cation/carnitine transporter), member 5 
(SLC22A5), and Platelet-derived growth factor receptor, beta (PDGFRB). 
SUPPLEMENTAL TABLE 1 displays all genes on the GR-signaling array and their 
associated p-values, fold change values, and standard error values.   
 To further investigate how iAs exposure modulates the GR-signaling pathway in 
placental cells, genome-wide DNA methylation was quantified using the 850k Illumina array 
(Wayne State, Detroit, MI). Significance was set at a Bonferroni-corrected p-value of p<0.05 
(McDonald, 2014). Additionally,  differences were calculated as  (treated)- (untreated) to 
determine how CpG methylation changed with treatment groups. When DNA methylation 
data was integrated with the expression data of the 12 significant (p<0.05) identified genes 
from the GR-signaling array (Qiagen, Valencia, California), 65 probes representing 12 GR-
signaling genes were found to have significantly altered levels of DNA methylation and 
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mRNA expression in treatment groups compared to controls. Of these genes, probes on all 12 
identified genes displayed changes representative of the transcription factor occupancy 
(TFO) theory in at least one treatment group. The term TFO patterning means the identified 
probes demonstrated either hypermethylation in association with decreased mRNA 
expression or hypomethylation in association with increased mRNA expression.  
 AFF1, SBSB1, AQP1, ARID5B, SLC22A5, and H6PD had at least one probe site that 
displayed TFO patterning across all treatment groups and represented in FIGURE 2.  
 
Figure 2. The six genes that displayed TFO patterning across all treatment groups. 
The six identified genes that displayed TFO patterning across all treatment groups indicating 
decreases in mRNA expression are associated with increases in methylation and increases in 
mRNA expression are associated with decreases in methylation. Significant alterations in 
beta differences are indicated with an asterisk.  
 
Specifically, AFF1 and SBSB1, displayed hypomethylation and an increase in gene 
expression compared to controls. Conversely, AQP1 displayed hypomethylation compared to 
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controls as treatment increased and had a subsequent relative decrease in mRNA expression. 
The other three genes, ARID5B, SLC22A5, and H6PD displayed a unique pattern where the 
0.5 M iAs treatment resulted in a decrease in methylation and an increase in mRNA 
expression, while 1 and 3 M iAs treatment groups displayed an increase in methylation and 
a decrease in mRNA expression relative to controls. The remaining six genes, PER2, 
CYB561, ZHX3, PDGFRB, SGK1, and MT2A displayed TFO patterning across some but not 
all treatments. In summary, half of the 12 identified genes had probes that displayed TFO 
patterning across all treatment groups signifying a relationship between placental DNA 
methylation alterations and mRNA expression in GR-signaling genes. Beta differences as 
well as beta values for all 12 identified genes that displayed significant (p<0.05) alterations 
in methylation and mRNA expression can be found in SUPPLEMENTAL TABLE 2. 
To identify canonical pathways, upstream targets, and functional outcomes associated 
with the 12 significant genes that displayed overlap between methylation altered GR-target 
gene expression identified network analysis was performed. For this analysis, IPA constructs 
networks based on relationships with the literature (Kramer, Green, Pollard, & Tugendreich, 
2014). Significant pathways associated with the gene set were identified using a right-tailed 
Fisher's Exact test.  
The 12 significant genes that displayed overlap between significant alterations in 
DNA methylation and mRNA expression can be found in SUPPLEMENTAL TABLE 2. 
Interestingly, one of the top canonical pathway associated with the identified gene set was 
the circadian rhythm signaling pathway (𝑝 =  1.84 ∙ 10−2). Diseases and functions 
associated were quantity of cells (𝑝 = 1.93 ∙ 10−4) and size of body (𝑝 = 3.06 ∙ 10−4), 
abnormal adrenal gland function (𝑝 =  4.30 ∙ 10−4), and diabetic complications (𝑝 =  5.85 ∙
13 
10−4), among others. Previous literature has supported the theory that environmentally-
responsive transcription factors influence CpG methylation patterns (Martin & Fry, 2016). 
Given this, to further investigate for transcription factor binding sites within the genes that 
displayed altered CpG methylation transcriptional regulators of GR-signaling genes were 
subsequently identified. Analysis revealed that the promoter region of the genes that 
displayed altered CpG methylation were enriched for binding sites of Tumor Necrosis Factor 
(TNF) (𝑝 =  1.79 ∙ 10−4). (TABLE 1). 
Table 1. Identified functional outcomes, diseases, canonical pathways, and transcription 
factor regulators of the 12 identified GR-signaling genes that displayed significant 
(p<0.05) alterations in mRNA expression and DNA methylation.  
Functional outcomes/TF regulators p-value, genes associated  
Tumor Necrosis Factor (TNF)  (𝑝 =  1.79 ∙ 10−4), AQP1, ARID5B, 
MT2A, PER2, SGK1, SPSB1 
Circadian Rhythm Signaling  (𝑝 =  1.84 ∙ 10−2), PER2 
Quantity of cells (𝑝 = 1.93 ∙ 10−4), AFF1, AQP1, 
ARID5B, MT2A, PDGFRB, PER2, SGK1 
Size of Body  (𝑝 = 3.06 ∙ 10−4), AFF1, AQP1, 
ARID5B, H6PD, PER2 
Diabetic Complications (𝑝 =  5.85 ∙ 10−4), AQP1, MT2A, 
PDFGRB 




CHAPTER 4: DISCUSSION 
 Millions of people around the world are exposed to inorganic arsenic (iAs) through 
contaminated drinking water (Naujokas et al., 2013). These exposures have been associated 
with adverse health outcomes in adult populations as well as adverse pregnancy and neonatal 
outcomes (Naujokas et al., 2013; Rahman et al., 2007). Furthermore, iAs exposure has been 
to act as an endocrine disruptor and has been shown to modulate the GR-signaling pathway, 
which is integral for adult stress response and fetal development (Zannas & Chrousos, 2017; 
Emin Turkay Korgun, 2012). In this study, we investigated how iAs modulates GR-target 
gene expression in placental cells and whether iAs exposure influences methylation patterns, 
which are associated with disease. Our results confirm our hypothesis that mRNA expression 
levels of downstream targets of the GR-signaling pathway were significantly altered in 
response to iAs exposure. Additionally, iAs exposure was shown to significantly alter CpG 
methylation patterning of GR-signaling genes in placental cells. Finally, the differentially 
modified genes observed in this study have been shown to be associated with placental 
physiology and fetal development (Guo et al., 2016; Salker et al., 2011; Tekin, Kayaalti, 
Aliyev, & Soylemezoglu, 2012; Grube et al., 2005; Chhabra et al., 2012). These results 
suggest that prenatal iAs exposure may disrupt the GR-signaling pathway in placental cells 
and that this disruption may have functional implications for DNA methylation patterning 
and health outcomes.  
 In support of arsenic’s role as an endocrine disruptor, we investigated the role that iAs 
exposure plays in modulating expression of a major endocrine pathway, the GR- signaling 
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pathway through the use of a Qiagen Human GR-signaling array. Results demonstrated a 
dose-response relationship amongst 12 genes that are targets of the GR-signaling pathway. 
These genes included Aquaporin 1 (AQP1), Metallothionein 2A (MT2A), AF4/FMR2 family, 
member 1 (AFF1), and Serum/GC-regulated kinase 1 (SGK1), among others. The observed 
dose-response of these genes is significant as many of these identified genes play a role in 
placental physiology and fetal growth and development. Specifically, AQP1, a maternally-
expressed gene, has been shown to be involved in successful placental growth and 
development (Guo et al., 2016). Previous studies have revealed the dysregulation of SGK1 to 
result in errors in embryonic implantation and cell survival (Salker et al., 2011). PDGFRB 
has been shown to regulate placental hematopoietic stem cell generation in trophoblast cells 
and also has been shown to prevent premature hematopoietic stem cell differentiation, which 
is important for proper fetal development (Chhabra et al., 2012). Additionally, in the placenta 
MT2A and SLC22 have been postulated to regulate the transfer of micronutrients to the fetus 
as well as the transfer of L-carnitine uptake, which is critical for fetal development (Tekin et 
al., 2012; Grube et al., 2005). 
Previous literature has demonstrated iAs’s ability to selectively alter glucocorticoid-
target gene expression at low, environmentally relevant doses (Bodwell et al., 2004; 
Kaltreider, Davis, Lariviere, & Hamilton, 2001). Specifically, higher doses of inorganic 
arsenic (1-3 M) induced an inhibition of gene expression while lower doses (0.5-1 M) 
show an induction of expression (Kaltreider et al., 2001). In this study, our data substantiated 
these findings as we observed low doses (0.5-1 M) of iAs to induce mRNA expression of 
GR-target genes in placental cells, while higher doses (1-3 M) repressed expression of GR-
target genes.  It must be noted that the extent to which iAs modulates the GR-signaling 
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pathway is largely dependent on the quantity of the GR present in the tissue of interest, 
indicating iAs effects on the GR-signaling pathway may differ by tissue type (Bodwell et al., 
2004). Of relevance to placental function,  previous studies have shown the GR gene, 
NR3C1, to be highly expressed in the placenta, which could explain differences in GR-target 
gene induction demonstrated in placental cells by this study (Conradt et al., 2013).  
To investigate whether iAs-induced alterations of GR-target gene expression is tied to 
altered CpG methylation patterns in placental cells, genome-wide methylation was evaluated 
with an 850 K Illumina Array.  Previous studies have shown that DNA methylation is able to 
influence mRNA gene expression of many genes in placental tissue and may serve as a 
mediating mechanism for iAs-induced health outcomes (Laine & Fry, 2016; Kile et al., 2014; 
Green et al., 2016; Sun et al., 2016). Our results displayed a total of 65 CpG sites 
representing 12 GR-target genes displayed both significantly altered CpG methylation and 
mRNA expression levels in relation to iAs exposure. Past literature has demonstrated 
inorganic arsenic to preferentially bind to the GR and alter the glucocorticoid’s ability to act a 
transcription factor in liver cells (Kaltreider et al., 2001). These findings suggest that when 
inorganic arsenic binds to the GR, the GR is able to bind to GREs and induce transcription at 
low doses but inhibit transcription at higher doses (Kaltreider et al., 2001).  
Transcription factor binding has been postulated to drive the transcription factor 
occupancy (TFO) theory. As previously mentioned, the TFO theory postulates that 
environmentally-responsive transcription factors influence methylation patterns by blocking 
the enzymes that methylate DNA from gaining access to the DNA sequence (Martin & Fry, 
2016). Interestingly, all 12 genes displayed patterning associated with the TFO theory in at 
least one treatment group, with half of these genes (n=6) displayed TFO patterning across all 
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treatments and the remaining six genes displayed TFO patterning across some but not all 
treatments. Interestingly, in three of the six genes that displayed TFO patterning across all 
treatments, H6PD, ARID5B and SLC22A5, increases in mRNA expression were associated 
with decreases in methylation at 0.5 M iAs treatment and at 1 and 3 M iAs decreases in 
mRNA expression were associated with hypermethylation relative to controls. Taken 
together, our findings in conjunction with existing literature suggest that inorganic arsenic is 
able to bind to the GR and induce expression at low doses while inhibiting expression at 
higher doses (Bodwell et al., 2004; Kaltreider et al., 2001). In addition to this, we have 
demonstrated that there is some interplay between the GR binding to GREs and DNA 
methylation patterning. This suggests that these observed arsenic-induced alterations in 





Figure 3. Graphic illustrating how iAs may modulate the GR signaling in a biological 
system at high and low doses of iAs.  
A. Glucocorticoid receptor (GR) binding to glucocorticoid response elements (GREs) under 
normal physiologic conditions, in human cells, and inducing dimerization, translocation, and 
induction of mRNA expression. B. At low levels, inorganic arsenic (iAs) may bind to GR 
and induce mRNA expression while denying DNMT access to the DNA sequence, resulting 
in an increase in mRNA expression and a decrease in CpG methylation. C. iAs exposure may 
result in DNA methylation, preventing the GR with iAs bound from binding to GREs, 
resulting in a decrease in mRNA expression. D. iAs also may bind to GR and repress mRNA 
expression, resulting in a decrease in mRNA expression and a decrease in CpG methylation.  
 
In our study, the observed CpG methylation patterning could be due to the fact the iAs 
selectively induces the expression of transcription factors along the GR-signaling pathway in 
placental cells in a dose-response manner. This altered binding of the GR as a transcription 
factor prevents DNA methylation enzymes (DNMT) from accessing GREs on the DNA, 
which ultimately reduces methylation levels and selectively increases mRNA  expression of 
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GR-target genes. Previous studies have postulated that higher doses of arsenic, which bind to 
the GR, induce allosteric changes in the DNA binding domain, ultimately altering target 
mRNA gene expression and subsequent methylation patterns, which we have demonstrated 
in this study (Bodwell et al., 2004). Altered methylation patterns in the placenta are 
significant as these epigenetic marks have been associated with gene expression alterations 
and adverse fetal health outcomes such as spontaneous abortion, infant mortality, altered 
cognitive functioning, higher rates of infant infection, and preterm birth (Naujokas et al., 
2013; Rahman et al., 2007; Appleton et al., 2017; Punshon et al., 2015). It must be noted that 
differences in methylation patterning and gene expression not associated with the TFO can 
potentially be explained through the impact of site-specific CpG methylation. Previous 
studies have suggested that the location of the methylation mark may serve as a differential 
driver of gene expression. Specifically, methylation in the promoter region of the genome has 
been shown to reduce mRNA expression while methylation in the gene body has been 
associated with an induction in mRNA expression (Rojas et al., 2015).  
In support of the TFO theory, we investigated the major upstream regulators of the 12 
identified GR-target genes that displayed both altered mRNA expression and CpG 
methylation patterns in response to iAs exposure. Size of body and quantity of cells were 
identified as major functional outcomes associated with the identified 12 genes. This is 
interesting as previous studies have demonstrated prenatal iAs exposure to be associated 
with, low infant birthweight, low gestational age, newborn length, and small head 
circumference (Laine et al., 2015; Gilbert-Diamond, Emond, Baker, Korrick, & Karagas, 
2016). Additionally, iAs has been associated with diabetes development, which has also 
identified as a functional outcome through IPA analysis (Farzan et al., 2016). The circadian 
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rhythm signaling pathway (𝑝 =  1.84 ∙ 10−2) was identified as a top canonical pathway 
associated with the 12 GR-target genes.  This is interesting as previous studies have 
postulated that the placenta may possess circadian properties, which affect fetal and placental 
physiology and development (Waddell, Wharfe, Crew, & Mark, 2012). Dysregulation of 
circadian genes have been implicated in the development of cancer and obesity (Froy, 2010). 
Furthermore, these results are substantiated by previous studies, which have shown 
glucocorticoids to play a role in circadian rhythm signaling and the regulation of pro-
inflammatory cytokines, such as TNF (Waddell et al., 2012; Mark, Wharfe, Lewis, & 
Waddell, 2011). In the current study, we identified binding sites of TNF (𝑝 =  1.79 ∙ 10−4) 
as the as the primary transcriptional regulator of the identified gene set. TNF has been shown 
to regulate observed proteomic alterations in response to prenatal iAs exposure in previous 
studies (Laine & Fry, 2016; Bailey et al., 2014). TNF serves as a modulator of cellular 
signaling pathways that  regulate cell growth and proliferation as well as inflammatory 
pathways (Holtmann & Neurath, 2004).  
 In summary, we investigated whether inorganic arsenic disrupts the expression levels 
of genes that act within the GR-pathway in JEG-3 placental cells. Our results have shown 
that GR-target genes are modulated by iAs exposure at increasing concentrations in placental 
cells. Furthermore, these expression alterations are at least partially related to DNA 
methylation patterning in placental cells, which has been implicated in functional adverse 
health outcomes associated with prenatal iAs exposure, placental physiology, and fetal 
development. These alterations in CpG methylation patterning provide support for the TFO 
theory as decreases in CpG methylation have been associated with increases in mRNA 
expression. The identified genes that display TFO patterning have been associated with 
 
21 
circadian signaling, growth and development, and endocrine function. Taken together, our 
data substantiates findings from previous studies, which have shown iAs to bind to the GR 
and selectively alter GR-target genes.  Our future work will aim to elucidate how inorganic 
arsenic alters the DNA Binding Domain of the GR in placental cells and to investigate how 











(0.5 vs. Control) 
p-value 
(1 vs. Control) 
p-value 
(3 vs. Control) 
Average Fold 
Change 0.5 As 
SE of 0.5 FC 
Average fold 
change 1 As 
SE 1 AS FC 
Average fold 
change 3 As 
SE 3 FC 
ADARB1 0.82 0.48 0.97 0.93 1.23 0.27 -1.04 0.05 -1.06 0.15 
AFF1 0.02 0.93 0.13 0.01 1.13 0.33 1.26 0.17 3.09 0.34 
AK2 0.78 0.46 0.95 0.56 1.17 0.23 -1.06 0.07 -1.02 0.03 
AMPD3 0.93 0.91 0.59 0.67 1.25 0.61 -1.15 0.19 -1.02 0.14 
ANGPTL4 0.25 0.39 0.53 0.26 1.31 0.15 -1.18 0.14 -1.25 0.05 
ANXA4 0.54 0.92 0.42 0.23 1.11 0.35 -1.35 0.16 -1.33 0.11 
AQP1 0.00 0.97 0.24 0.00 -1.05 0.17 -2.14 0.14 -10.04 0.02 
ARID5B 0.03 0.42 0.10 0.04 1.05 0.13 -1.81 0.07 -2.30 0.03 
ASPH 0.12 0.99 0.32 0.04 1.04 0.22 -1.25 0.10 -2.34 0.08 
ATF4 0.38 0.55 0.43 0.40 1.08 0.10 -1.09 0.10 1.16 0.05 
BCL6 0.86 0.71 0.44 0.57 1.20 0.32 -1.26 0.18 -1.08 0.07 
BMPER 0.46 0.96 0.19 0.94 N/A N/A -1.69 0.27 N/A N/A 
CALCR N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
CEBPA 0.89 0.74 0.91 0.49 1.35 0.31 1.10 0.07 1.08 0.03 
CEBPB 0.36 0.34 0.93 0.17 1.40 0.46 -1.08 0.09 1.24 0.03 
COL4A2 0.73 0.83 0.52 0.50 1.24 0.16 -1.06 0.06 -1.08 0.07 
CREB1 0.83 0.41 0.52 0.55 1.29 0.20 1.06 0.07 1.01 0.08 
CREB3 0.33 0.94 0.47 0.11 1.08 0.12 1.05 0.06 1.33 0.07 
CREB3L4 0.30 0.45 1.00 0.24 1.11 0.20 1.00 0.03 -1.51 0.05 
CTGF 0.81 0.99 0.56 0.48 1.02 0.11 1.01 0.16 -1.14 0.09 
CYB561 0.05 0.91 0.06 0.03 1.09 0.13 -1.43 0.05 -1.79 0.00 
DDIT4 0.39 0.67 0.43 0.36 1.75 0.75 1.04 0.63 1.96 0.08 










(0.5 vs. Control) 
p-value 
(1 vs. Control) 
p-value 
(3 vs. Control) 
Average Fold 
Change 0.5 As 
SE of 0.5 FC 
Average fold 
change 1 As 
SE 1 AS FC 
Average fold 
change 3 As 
SE 3 FC 
DUSP1 0.19 0.40 0.49 0.04 1.17 0.18 1.02 0.08 1.93 0.11 
EDN1 0.85 0.42 0.54 0.70 4.96 3.88 1.98 0.30 1.48 0.38 
EHD3 0.17 0.52 0.06 0.10 1.11 0.47 -1.97 0.11 -1.62 0.08 
ERRFI1 0.88 0.86 0.98 0.51 1.23 0.35 -1.02 0.07 1.17 0.13 
FKBP5 0.36 0.19 0.89 0.20 1.82 0.35 1.27 0.43 N/A 
#VALU
E! 
FOSL2 0.09 0.82 0.20 0.04 1.26 0.44 -1.63 0.08 -2.61 0.01 
GDPD1 0.19 0.76 0.16 0.16 1.38 0.54 -1.87 0.13 -1.96 0.08 
GHRHR 0.35 0.19 0.72 0.57 N/A N/A -1.64 0.14 -1.07 0.31 
GLUL 0.08 0.85 0.08 0.06 1.16 0.22 -1.25 0.03 -1.38 0.02 
GOT1 0.77 0.88 0.52 0.54 1.16 0.17 -1.03 0.06 1.00 0.04 
H6PD 0.03 0.33 0.22 0.03 1.19 0.13 -1.41 0.04 -2.45 0.02 
HAS2 0.96 0.75 0.92 0.98 N/A N/A N/A N/A N/A N/A 
HNRPLL 0.83 0.42 0.50 0.51 1.21 0.17 1.06 0.06 1.04 0.05 
IL10 0.90 0.98 0.95 0.58 1.77 1.30 1.22 0.56 1.10 0.76 
IL1RN 0.32 0.32 0.42 0.83 1.24 0.20 #REF! 0.13 35.30 0.70 
IL6 0.08 0.55 0.06 0.02 2.12 0.95 3.55 0.64 4.66 0.32 
IL6R 0.80 0.99 0.87 0.44 N/A N/A N/A N/A 3.14 1.21 
KLF13 0.06 0.26 0.28 0.09 1.26 0.20 -1.21 0.04 1.14 0.05 
KLF9 0.50 0.44 0.81 0.46 1.27 0.26 -1.21 0.15 -1.17 0.06 
LOX 0.93 0.64 0.91 0.93 1.27 0.50 -1.04 0.27 1.06 0.38 
MERTK C 0.05 0.27 0.91 0.06 1.22 0.10 1.08 0.11 -1.35 0.01 
MT1E 0.62 0.40 0.74 0.91 N/A N/A N/A N/A N/A N/A 
MT2A 0.01 0.95 0.54 0.00 1.47 0.32 11.37 7.68 80.07 24.91 










(0.5 vs. Control) 
p-value 
(1 vs. Control) 
p-value 
(3 vs. Control) 
Average Fold 
Change 0.5 As 
SE of 0.5 FC 
Average fold 
change 1 As 
SE 1 AS FC 
Average fold 
change 3 As 
SE 3 FC 
NR3C1 0.09 0.99 0.10 0.05 1.07 0.29 -1.96 0.04 -2.39 0.03 
PDCD7 0.39 0.89 0.18 1.00 1.13 0.16 -1.08 0.04 -1.00 0.07 
PDGFRB 0.01 0.03 0.42 0.10 1.85 0.53 1.06 0.06 -1.86 0.07 
PDP1 0.15 0.27 0.10 0.04 1.26 0.17 1.14 0.05 1.62 0.10 
PER1 0.61 0.32 0.88 0.98 1.70 0.67 -1.13 0.18 -1.02 0.08 
PER2 0.00 0.86 0.02 0.00 1.17 0.19 -2.14 0.04 -5.19 0.02 
PIK3R1 0.15 0.48 0.07 0.06 1.08 0.28 -1.40 0.06 -1.56 0.03 
PLD1 Ph 0.25 0.33 0.97 0.27 1.32 0.28 -1.04 0.05 -1.46 0.04 
PLEKHF1 0.85 0.90 0.80 0.56 1.17 0.24 -1.19 0.21 1.05 0.08 
POU2F1 0.09 0.68 0.12 0.08 1.38 0.30 -1.21 0.08 -1.46 0.07 
POU2F2 0.79 0.56 0.70 0.86 1.98 0.84 1.17 0.52 1.35 0.44 
RASA3 0.54 0.19 0.56 0.81 2.07 0.96 1.50 0.73 1.48 0.72 
RGS2 0.28 0.49 0.96 0.11 1.07 0.18 -1.05 0.03 1.44 0.41 
RHOB 0.06 0.84 0.06 0.04 1.16 0.11 -1.36 0.03 -1.54 0.04 
RHOJ 0.90 0.85 0.78 0.67 2.58 2.01 2.33 1.40 1.72 1.33 
SESN1 0.10 0.84 0.10 0.07 1.18 0.22 -1.13 0.08 -1.33 0.07 
SGK1 0.03 0.06 0.53 0.14 -1.46 0.18 1.05 0.23 1.91 0.20 
SLC10A6 0.52 0.52 0.16 0.49 1.71 0.79 2.52 0.78 1.74 0.81 
SLC19A2 0.29 0.39 0.98 0.11 1.21 0.24 1.03 0.07 1.41 0.09 
SLC22A5 0.04 0.27 0.31 0.05 1.27 0.09 -1.15 0.12 -1.51 0.03 
SNTA1 0.44 0.70 0.50 0.13 1.26 0.41 -1.09 0.08 -1.45 0.02 
SPHK1 0.98 0.70 0.80 0.75 2.31 1.76 1.69 1.05 1.23 0.30 
SPSB1 0.04 0.32 0.10 0.01 1.21 0.17 1.17 0.06 2.58 0.12 
STAT5A 0.60 0.67 0.80 0.42 2.31 1.53 3.75 3.26 -2.68 0.16 










(0.5 vs. Control) 
p-value 
(1 vs. Control) 
p-value 
(3 vs. Control) 
Average Fold 
Change 0.5 As 
SE of 0.5 FC 
Average fold 
change 1 As 
SE 1 AS FC 
Average fold 
change 3 As 
SE 3 FC 
TBL1XR1 0.08 0.85 0.08 0.06 1.16 0.20 -1.21 0.04 -1.34 0.03 
TNF 0.10 0.04 0.66 ? N/A 0.46 -1.23 0.11 N/A 0.17 
TNFAIP3 0.83 0.72 0.61 0.92 1.48 1.92 -1.02 0.59 1.13 0.21 
TSC22D3 0.39 0.72 0.61 0.21 2.53 0.35 -1.07 0.18 -2.47 0.15 
USP2 0.31 0.38 0.44 0.08 1.33 0.17 1.22 0.11 1.85 0.06 
USP54 0.17 0.20 0.29 0.41 1.42 0.34 1.21 0.06 -1.02 N/A 
VDR 0.54 0.29 0.67 ? -1.53 0.31 -2.82 0.12 N/A N/A 
VLDLR 0.59 0.62 0.58 0.46 1.11 0.25 1.02 0.21 N/A 0.09 
XDH 0.05 0.06 0.76 0.26 1.56 0.36 -1.13 0.03 -1.36 0.03 
ZFP36 0.21 0.89 0.43 0.17 1.17 0.08 -1.09 0.10 1.08 0.07 
ZHX3 0.05 0.09 0.79 0.16 1.18 0.20 -1.18 0.10 -1.52 0.04 
NF281 0.08 0.85 0.08 0.06 1.23 0.00 1.11 0.00 1.03 0.00 
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4587 0.01 0.41 Body AFF1 0.90 0.91 0.01 0.90 0.00 0.92 0.02 Body 0.02 0.93 0.13 0.01 1.13 1.26 3.09 
cg0371
4884 0.05 0.50 Body AFF1 0.93 0.95 0.02 0.94 0.01 0.95 0.02 Body 0.02 0.93 0.13 0.01 1.13 1.26 3.09 
cg0849
4390 0.01 0.40 
Body;Bo
dy AFF1 0.28 0.27 -0.01 0.26 -0.02 0.24 -0.03 Body;Body 0.02 0.93 0.13 0.01 1.13 1.26 3.09 
cg1727
9557 0.02 0.44 
Body;TS
S1500 AFF1 0.04 0.04 0.00 0.04 0.00 0.04 0.00 
Body;TSS15
00 0.02 0.93 0.13 0.01 1.13 1.26 3.09 
cg1917
0233 0.05 0.50 
TSS1500
;Body AFF1 0.70 0.67 -0.02 0.72 0.02 0.67 -0.02 
TSS1500;Bo
dy 0.02 0.93 0.13 0.01 1.13 1.26 3.09 
cg1932
0820 0.02 0.43 
Body;Bo
dy AFF1 0.43 0.41 -0.02 0.37 -0.06 0.37 -0.06 Body;Body 0.02 0.93 0.13 0.01 1.13 1.26 3.09 
cg2157
1135 0.02 0.43 
Body;Bo
dy AFF1 0.42 0.40 -0.01 0.34 -0.08 0.31 -0.11 Body;Body 0.02 0.93 0.13 0.01 1.13 1.26 3.09 
cg2455
1420 0.02 0.44 TSS200 AFF1 0.06 0.06 0.00 0.06 0.00 0.06 0.01 TSS200 0.02 0.93 0.13 0.01 1.13 1.26 3.09 
cg1013
2917 0.01 0.40 1stExon AQP1 0.76 0.79 0.03 0.78 0.01 0.78 0.02 1stExon 0.00 0.97 0.24 0.00 -1.05 -2.14 -10.04 
cg1808
0604 0.04 0.49 
1stExon;
5'UTR AQP1 0.75 0.79 0.04 0.77 0.02 0.75 0.00 
1stExon;5'U
TR 0.00 0.97 0.24 0.00 -1.05 -2.14 -10.04 
cg1830
7978 0.05 0.50 Body AQP1 0.70 0.72 0.02 0.71 0.01 0.73 0.03 Body 0.00 0.97 0.24 0.00 -1.05 -2.14 -10.04 
cg2128
9714 0.01 0.42 TSS1500 AQP1 0.74 0.76 0.02 0.75 0.01 0.77 0.03 TSS1500 0.00 0.97 0.24 0.00 -1.05 -2.14 -10.04 
cg0302
8088 0.01 0.39 
Body;Bo
dy ARID5B 0.67 0.68 0.01 0.69 0.01 0.73 0.06 Body;Body 0.03 0.42 0.10 0.04 1.05 -1.81 -2.30 
cg0685
4180 0.00 0.32 Body ARID5B 0.89 0.90 0.01 0.86 -0.03 0.89 0.00 Body 0.03 0.42 0.10 0.04 1.05 -1.81 -2.30 
cg0824
1406 0.05 0.50 
TSS200;
Body ARID5B 0.58 0.58 0.01 0.59 0.02 0.60 0.02 
TSS200;Bod
y 0.03 0.42 0.10 0.04 1.05 -1.81 -2.30 
cg1763
3222 0.01 0.42 
TSS1500
;Body ARID5B 0.91 0.91 0.01 0.91 0.01 0.92 0.02 
TSS1500;Bo
dy 0.03 0.42 0.10 0.04 1.05 -1.81 -2.30 
cg1852
2931 0.05 0.50 Body ARID5B 0.78 0.78 0.00 0.79 0.00 0.84 0.05 Body 0.03 0.42 0.10 0.04 1.05 -1.81 -2.30 
cg1898





















































8847 0.02 0.46 
Body;Bo
dy ARID5B 0.92 0.90 -0.02 0.91 -0.01 0.92 0.01 Body;Body 0.03 0.42 0.10 0.04 1.05 -1.81 -2.30 
cg2278
2105 0.01 0.40 Body ARID5B 0.90 0.85 -0.04 0.87 -0.03 0.87 -0.02 Body 0.03 0.42 0.10 0.04 1.05 -1.81 -2.30 
cg2449
5062 0.01 0.39 Body ARID5B 0.76 0.76 0.01 0.72 -0.04 0.73 -0.03 Body 0.03 0.42 0.10 0.04 1.05 -1.81 -2.30 
cg2600
2628 0.03 0.48 TSS1500 ARID5B 0.06 0.06 0.00 0.06 0.00 0.06 0.00 TSS1500 0.03 0.42 0.10 0.04 1.05 -1.81 -2.30 
cg0498
7499 0.02 0.46 
TSS1500
;TSS150
0 CYB561 0.50 0.51 0.01 0.48 -0.02 0.50 0.00 
TSS1500;TS
S1500 0.05 0.91 0.06 0.03 1.09 1.09 -1.43 
cg1144
2173 0.04 0.49 
5'UTR;5'
UTR;5'U
TR CYB561 0.97 0.97 0.00 0.97 0.01 0.96 0.00 
5'UTR;5'UT
R;5'UTR 0.05 0.91 0.06 0.03 1.09 1.09 -1.43 
cg1311
8906 0.04 0.48 
TSS1500
;TSS150
0 CYB561 0.44 0.47 0.03 0.43 -0.02 0.44 0.00 
TSS1500;TS
S1500 0.05 0.91 0.06 0.03 1.09 1.09 -1.43 
cg1152
1888 0.05 0.50 
5'UTR;T
SS1500 H6PD 0.71 0.73 0.02 0.74 0.03 0.75 0.04 
5'UTR;TSS1
500 0.03 0.33 0.22 0.03 1.19 -1.41 -2.45 
cg1409
4793 0.04 0.49 Body H6PD 0.85 0.87 0.02 0.85 0.01 0.87 0.02 Body 0.03 0.33 0.22 0.03 1.19 -1.41 -2.45 
cg1625
6342 0.02 0.46 3'UTR H6PD 0.71 0.73 0.02 0.71 0.00 0.71 0.00 3'UTR 0.03 0.33 0.22 0.03 1.19 -1.41 -2.45 
cg1780
5199 0.01 0.42 Body H6PD 0.57 0.58 0.00 0.59 0.02 0.61 0.03 Body 0.03 0.33 0.22 0.03 1.19 -1.41 -2.45 
cg2519
0094 0.02 0.44 Body H6PD 0.85 0.88 0.03 0.86 0.01 0.89 0.04 Body 0.03 0.33 0.22 0.03 1.19 -1.41 -2.45 
cg2726
6479 0.01 0.40 
5'UTR;1s
tExon H6PD 0.19 0.19 0.00 0.20 0.01 0.22 0.02 
5'UTR;1stEx
on 0.03 0.33 0.22 0.03 1.19 -1.41 -2.45 
cg0671
1418 0.01 0.39 3'UTR MT2A 0.91 0.93 0.01 0.91 -0.01 0.92 0.01 3'UTR 0.01 0.95 0.54 0.00 1.47 11.37 80.07 
cg0417
3992 0.01 0.43 5'UTR PDGFRB 0.78 0.79 0.00 0.79 0.01 0.82 0.04 5'UTR 0.01 0.03 0.42 0.10 1.85 1.06 -1.86 
cg0552
6146 0.04 0.49 5'UTR PDGFRB 0.71 0.73 0.02 0.72 0.01 0.74 0.03 5'UTR 0.01 0.03 0.42 0.10 1.85 1.06 -1.86 
cg2624





















































6543 0.04 0.49 TSS1500 PER2 0.06 0.06 0.00 0.07 0.01 0.06 0.00 TSS1500 0.00 0.86 0.02 0.00 1.17 -2.14 -5.19 
cg0411
7792 0.04 0.49 Body PER2 0.84 0.86 0.02 0.84 0.00 0.84 0.00 Body 0.00 0.86 0.02 0.00 1.17 -2.14 -5.19 
cg0617
4546 0.03 0.48 Body PER2 0.92 0.94 0.02 0.93 0.01 0.92 0.00 Body 0.00 0.86 0.02 0.00 1.17 -2.14 -5.19 
cg2014
6792 0.00 0.34 Body PER2 0.87 0.86 0.00 0.84 -0.02 0.83 -0.04 Body 0.00 0.86 0.02 0.00 1.17 -2.14 -5.19 
cg0290
4344 0.04 0.49 
Body;1st
Exon;5'U
TR SGK1 0.74 0.76 0.02 0.76 0.03 0.79 0.06 
Body;1stExo
n;5'UTR 0.03 0.06 0.53 0.14 -1.46 1.05 1.91 
cg0406
0943 0.02 0.44 Body SGK1 0.88 0.90 0.01 0.89 0.00 0.87 -0.02 Body 0.03 0.06 0.53 0.14 -1.46 1.05 1.91 
cg0490
5719 0.03 0.47 Body SGK1 0.16 0.16 0.00 0.16 0.00 0.12 -0.04 Body 0.03 0.06 0.53 0.14 -1.46 1.05 1.91 
cg1568
0307 0.05 0.50 Body SGK1 0.77 0.76 -0.02 0.80 0.03 0.80 0.02 Body 0.03 0.06 0.53 0.14 -1.46 1.05 1.91 
cg1751

















Body 0.03 0.06 0.53 0.14 -1.46 1.05 1.91 
cg2073
1573 0.00 0.33 Body SGK1 0.88 0.90 0.02 0.90 0.02 0.90 0.02 Body 0.03 0.06 0.53 0.14 -1.46 1.05 1.91 
cg0397
9695 0.04 0.49 
Body;Bo
dy SLC22A5 0.86 0.86 0.00 0.89 0.03 0.86 0.00 Body;Body 0.04 0.27 0.31 0.05 1.27 -1.15 -1.51 
cg0668
7184 0.05 0.50 
Body;Bo
dy SLC22A5 0.45 0.45 0.00 0.45 -0.01 0.41 -0.04 Body;Body 0.04 0.27 0.31 0.05 1.27 -1.15 -1.51 
cg1602
2017 0.01 0.41 
Body;Bo
dy SLC22A5 0.76 0.78 0.02 0.77 0.00 0.74 -0.02 Body;Body 0.04 0.27 0.31 0.05 1.27 -1.15 -1.51 
cg1664





















































0266 0.03 0.46 Body SLC22A5 0.78 0.79 0.01 0.76 -0.02 0.75 -0.03 Body 0.04 0.27 0.31 0.05 1.27 -1.15 -1.51 
cg1915
7439 0.03 0.47 
Body;Bo
dy SLC22A5 0.83 0.83 0.00 0.81 -0.02 0.80 -0.02 Body;Body 0.04 0.27 0.31 0.05 1.27 -1.15 -1.51 
cg1917
3554 0.04 0.49 
1stExon;
1stExon;
TSS1500 SLC22A5 0.49 0.49 -0.01 0.48 -0.01 0.49 0.00 
1stExon;1stE
xon;TSS150
0 0.04 0.27 0.31 0.05 1.27 -1.15 -1.51 
cg2308
3514 0.03 0.47 
1stExon;
1stExon;
TSS200 SLC22A5 0.40 0.39 -0.01 0.40 -0.01 0.38 -0.02 
1stExon;1stE
xon;TSS200 0.04 0.27 0.31 0.05 1.27 -1.15 -1.51 
cg2664
7941 0.03 0.48 
Body;Bo
dy SLC22A5 0.84 0.84 0.00 0.85 0.02 0.86 0.02 Body;Body 0.04 0.27 0.31 0.05 1.27 -1.15 -1.51 
cg0311
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